Free Trial
→ You’re Being LIED To About The Iran War (From Banyan Hill Publishing) (Ad)tc pixel Free BCT Stock Alerts

BriaCell Therapeutics (BCT) Competitors

BriaCell Therapeutics logo
C$5.49 -0.05 (-0.90%)
As of 03:59 PM Eastern
Compare

BCT vs. HBP, SCYB, COM, NVH, and IGX

Should you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and IntelGenx Technologies (IGX). These companies are all part of the "biotechnology" industry.

How does BriaCell Therapeutics compare to Helix BioPharma?

Helix BioPharma (TSE:HBP) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Helix BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$14.42N/A

In the previous week, BriaCell Therapeutics' average media sentiment score of 1.47 beat Helix BioPharma's score of 0.67 indicating that BriaCell Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Helix BioPharma Positive
BriaCell Therapeutics Positive

Helix BioPharma's return on equity of -36.79% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -36.79% -279.98%
BriaCell Therapeutics N/A -221.75%-122.71%

Helix BioPharma has a beta of 0.403644, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.947765, meaning that its share price is 95% more volatile than the S&P 500.

0.0% of Helix BioPharma shares are owned by institutional investors. Comparatively, 0.1% of BriaCell Therapeutics shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by insiders. Comparatively, 9.3% of BriaCell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

BriaCell Therapeutics beats Helix BioPharma on 7 of the 9 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Scythian Biosciences?

Scythian Biosciences (CVE:SCYB) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

In the previous week, BriaCell Therapeutics' average media sentiment score of 1.47 beat Scythian Biosciences' score of 0.00 indicating that BriaCell Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Scythian Biosciences Neutral
BriaCell Therapeutics Positive

Scythian Biosciences' return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Scythian BiosciencesN/A N/A N/A
BriaCell Therapeutics N/A -221.75%-122.71%

0.1% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scythian BiosciencesN/AN/AN/AN/AN/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$14.42N/A

Summary

BriaCell Therapeutics beats Scythian Biosciences on 3 of the 5 factors compared between the two stocks.

How does BriaCell Therapeutics compare to 138267 (COM.TO)?

BriaCell Therapeutics (TSE:BCT) and 138267 (COM.TO) (TSE:COM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, BriaCell Therapeutics' average media sentiment score of 1.47 beat 138267 (COM.TO)'s score of 0.00 indicating that BriaCell Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
BriaCell Therapeutics Positive
138267 (COM.TO) Neutral

138267 (COM.TO)'s return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -221.75% -122.71%
138267 (COM.TO) N/A N/A N/A

0.1% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$14.42N/A
138267 (COM.TO)N/AN/AN/AN/AN/A

Summary

BriaCell Therapeutics beats 138267 (COM.TO) on 3 of the 5 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Novoheart?

BriaCell Therapeutics (TSE:BCT) and Novoheart (CVE:NVH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, BriaCell Therapeutics' average media sentiment score of 1.47 beat Novoheart's score of 0.00 indicating that BriaCell Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
BriaCell Therapeutics Positive
Novoheart Neutral

Novoheart's return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -221.75% -122.71%
Novoheart N/A N/A N/A

0.1% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BriaCell Therapeutics has higher earnings, but lower revenue than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$14.42N/A
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A

Summary

BriaCell Therapeutics beats Novoheart on 5 of the 9 factors compared between the two stocks.

How does BriaCell Therapeutics compare to IntelGenx Technologies?

IntelGenx Technologies (CVE:IGX) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

In the previous week, BriaCell Therapeutics' average media sentiment score of 1.47 beat IntelGenx Technologies' score of 0.00 indicating that BriaCell Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
IntelGenx Technologies Neutral
BriaCell Therapeutics Positive

IntelGenx Technologies' return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
IntelGenx TechnologiesN/A N/A N/A
BriaCell Therapeutics N/A -221.75%-122.71%

BriaCell Therapeutics has lower revenue, but higher earnings than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntelGenx TechnologiesC$1.75M49.95-C$11.74M-C$0.08N/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$14.42N/A

0.1% of BriaCell Therapeutics shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

BriaCell Therapeutics beats IntelGenx Technologies on 5 of the 9 factors compared between the two stocks.

Get BriaCell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCT vs. The Competition

Export
MetricBriaCell TherapeuticsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$39.80MC$446.06MC$6.25BC$11.72B
Dividend Yield13.70%3.86%2.73%6.22%
P/E Ratio-0.384.1929.0423.83
Price / SalesN/A6,879.71476.4813.46
Price / CashN/A13.1327.6282.69
Price / Book0.5177.749.674.48
Net Income-C$2.37M-C$96.07MC$3.55BC$300.68M
7 Day Performance-0.54%0.71%1.70%0.12%
1 Month Performance-2.66%3.87%5.62%2.88%
1 Year Performance-89.64%48.54%34.42%57.78%

BriaCell Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCT
BriaCell Therapeutics
N/AC$5.49
-0.9%		N/AN/AC$39.80MN/AN/A16
HBP
Helix BioPharma
N/AC$2.02
+6.9%		N/AN/AC$154.28MN/AN/A9
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/AN/AC$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/AN/AC$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:BCT) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel